Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances
The use of compounded bioidentical hormone therapies (cBHTs) — an increasingly popular approach to relieve symptoms of menopause and male hypogonadism — should be limited to the small number of patients who cannot benefit from an FDA-approved hormone therapy product, says a new report from the National Academies of Sciences, Engineering, and Medicine.
More from Science & TechnologyMore posts in Science & Technology »
- COVID-Overwhelmed Hospitals Strain Staff and Hope to Avoid Rationing Care
- How Biden’s Climate Ambitions Could Shift America’s Global Footprint
- Thinking about open sourcing embedded scripting library (VM & Compiler)
- Servo motor control using IoT technology.
- The Battle Lines Are Forming in Biden’s Climate Push